Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary

August 4, 2022

NASDAQ US Health Care Pharmaceuticals earnings 61 min

Earnings Call Speaker Segments

Vivian Wu

executive
#1

Chad, thank you — and a good afternoon to everyone. It means a lot that you're spending part of your day with us. Joining this call are our President and CEO, Howard Robin; our Chief of Research and Development, Dr. Jonathan Zalevsky; Jill Thomsen, who is our Chief Financial Officer; and Brian Kotzin, our Chief Medical Officer. On today's call, we expect to share statements that look ahead regarding our company. These will cover things like how much therapeutic promise our drug candidates and research programs hold, plus how we plan to develop them going forward. We'll also discuss when we intend to begin clinical studies and when clinical data for those drug candidates might become available. Other topics include the schedule and plans for presenting future clinical data, details about our collaboration arrangements and how they might progress or succeed, what we expect to come out of our corporate restructuring and reorganization process, our financial guidance, and various other remarks about where our business is headed. Because these forward-looking statements deal with what hasn't happened yet, they come with uncertainties and risks that are difficult to foresee, and a great many of them are outside our ability to control. The results we report might end up looking quite different from what these statements suggest. You'll find the major risks and uncertainties laid out in the Form 10-Q that was submitted on May 6, 2022, available through sec.gov. Nothing obligates us to revise these forward-looking statements, whether that's prompted by fresh information, later events, or any other reason. Those interested can reach a webcast of today's call through the IR section on Nektar's site, nektar.com. Before handing things over to Howard, one more note: because each of us is joining by phone from a separate place, I'll be running the Q&A portion on behalf of our team, which should help us steer clear of any technical hiccups along the way; thank you for bearing with us. At this point, I'd like to turn things over to Howard Robin, our President and CEO. Howard?

Howard Robin

executive
#2

Appreciate that, Vivian. And thank you all for being here with us today. After the fresh strategic plan and the reorganization we made public in April, I'm happy to say we've achieved strong headway in carrying out that plan across the past few months. What we've accomplished lets us concentrate on the key biologic therapeutic candidates we're advancing here at Nektar, and we feel those candidates offer chances to deliver meaningful value for our shareholders in the years ahead. Three central R&D pillars form the foundation of our updated strategic plan, and we're confident they can produce value-enhancing milestones for the company: NKTR-358, our Treg stimulator program that we're partnering with Eli Lilly on and developing across multiple autoimmune diseases; NKTR-255, our novel IL-15 agonist that we fully own and are developing in multiple liquid tumor settings; plus a number of encouraging preclinical programs that came out of our immunology and oncology research. Every one of these programs stands as a separate and very promising chance to give patients scientifically distinct mechanisms spanning a variety of therapeutic areas. Let's begin with NKTR-358. This novel first-in-class regulatory T-cell stimulator is in development for autoimmune and inflammatory conditions including lupus and atopic dermatitis. A major element of our new operating plan involves funding a development participation capped at 25% in this crucial autoimmune program. For Nektar, that works out to a royalty in the low 20% range. This choice rested on our confidence in the science and in the encouraging data produced so far for NKTR-358, along with the enormous size of the markets we're going after. Within the U.S. by itself, close to 160,000 individuals are fighting lupus, and roughly 16 million individuals are living with atopic dermatitis, with 3 out of 4 of those dealing with moderate or severe disease. And in these indications, where sales of current agents run anywhere from $12 billion to $15 billion, a very high unmet medical need persists for patients. Consequently, given its standing as a potentially new mechanism for aiding patients with lupus and atopic dermatitis, NKTR-358 is positioned to be a substantial value driver for our company. Lilly has also signaled it will pursue an additional Phase II study in an autoimmune indication that has yet to be announced, which might begin in 2023. Enrollment in the Phase II lupus study is now complete, and we anticipate data from that study during the first half of 2023. This marks the initial Phase II data for NKTR-358, and should we succeed, it could soon afterward lead to a Phase III program in lupus; back in May, the study passed an interim analysis successfully, based on 60% of patients, and we're especially happy that the study continues as planned without any modifications. In a few minutes, Brian will share more specifics about our ongoing clinical progress and when upcoming data readouts are expected. Our oncology IL-15 agonist program, NKTR-255, is progressing nicely as well. The focus of our updated strategic plan is a near-term approach to development that puts the largest opportunities first, including the significant rise of cell therapy as a field. Later in this call, JZ will go through NKTR-255 in depth and walk through our new research programs, but right now I want to call out several important achievements from Q2. To start, Merck KGaA, our partner, launched the JAVELIN Bladder Medley Study, which pairs NKTR-255 with avelumab in the maintenance bladder setting — a setting where avelumab holds approval and currently generates roughly $500 million in yearly sales. It's very encouraging to us that Merck feels the same excitement we do about NKTR-255 and what it could do for bladder cancer patients. In the registrational trial of avelumab, patients whose natural killer cell levels were higher experienced improved outcomes when given avelumab as maintenance treatment. So adding an NK mobilizing agent like NKTR-255 to avelumab is very logical. We're additionally putting together a tightly focused plan for NKTR-255 in cell therapy. At the outset, what we're mainly aiming for is a Phase II trial sponsored by Nektar that combines NKTR-255 with the approved autologous CAR-T therapies YESCARTA and BREYANZI in diffuse large B-cell lymphoma. Since these agents won approval in the second-line DLBCL setting, their growth has been substantial, and revenue from them in second and third line should climb to a combined $3 billion or more. Through the inclusion of several approved therapies in our trial, we aim to establish NKTR-255 as the cell therapy potentiator of choice, one that might give patients responses that are better and last longer. We closed out the second quarter with about $625 million in cash, and crucially, our updated plan gives us a cash runway extending through the first half of 2025; we expect no need to raise capital over that stretch; this matters enormously to our business since, as you're aware, capital is hard to come by in the biotech market these days. Our distinctive standing in this sector provides the financial strength needed to carry out the new strategic plan and move our key programs ahead toward value generating data and milestones. I'll hand the call over now to Brian for an update on NKTR-358. Brian?

Brian Kotzin

executive
#3

I appreciate that, Howard. NKTR-358 stands apart as a distinctive compound, and the effort we're putting into this groundbreaking mechanism within autoimmune disease genuinely energizes me. Lilly just secured approval for the generic name of NKTR-358, which is respegaldesleukin — shortened to RESPEG. It's great to witness Lilly's ongoing commitment to this initiative, and on a personal level, I'm eager to keep collaborating with the Lilly group to help move this program forward. When it comes to 358, we took an entirely distinct route using our PEGylation chemistry to harness IL-2's immune-regulating capacity by targeting regulatory T cells, known as Tregs, in a specific way. What we're aiming for with this initiative is to tackle the fundamental Treg abnormalities present in autoimmune disease and to create a molecule resembling IL-2 that might stimulate Tregs selectively and more effectively than low-dose IL-2. Findings that came out of this program, in both lupus and atopic dermatitis, have strengthened our belief in this strategy. In the Phase Ib multiple ascending dose trial evaluating RESPEG against placebo among lupus patients, RESPEG produced a dose-dependent decrease in lupus skin disease activity, as assessed through the CLASI activity score and the subgroup of 22 patients whose baseline CLASI score was at least 4. Those results, combined with the PK, PD, and safety data gathered during our Phase Ib lupus trial, prompted Lilly to initiate a Phase II dose range binding study involving 280 patients. To reiterate, the Phase II trial evaluates multiple doses of NKTR-358 against placebo across a 24-week treatment period. As Howard noted, back in May, the interim assessment committee examined interim efficacy and safety data from the Phase II lupus study. The committee reviewed information from roughly 60% of patients who had finished the 24-week treatment period. We were pleased to learn that the interim assessment committee advised continuing the study through to completion without any modification. Enrollment for the study is now complete, and we remain on schedule to share data from it during the first half of 2023. In December of 2021, Lilly disclosed the first initial proof-of-concept data for the second dermatologic condition we're investigating with RESPEG, which is moderate to severe atopic dermatitis. The 12-week Phase Ib study run by Lilly tested 2 doses of RESPEG against placebo, then tracked patients for 36 additional weeks following their last dose of therapy. Treatment with RESPEG demonstrated a dose-dependent decrease in eczema area and severity index scores among patients, also referred to as the EASI score, with roughly a 70% reduction in scores at week 12 at the highest dose tested. What we observed at 12 weeks of treatment with RESPEG matches what shows up after 16 weeks of treatment with DUPIXENT, which is the current standard of care. But the most fascinating finding from the study, clearly, was that when we examined patients 36 weeks after dosing with RESPEG was stopped, their skin scores stayed very low and actually fell even more over that extended period — something not seen with DUPIXENT. That has made us and Lilly quite enthusiastic about the durability potential for RESPEG in atopic dermatitis. Full efficacy and safety data from this Phase Ib study are going to be presented at the 2022 EADV European Dermatology Meeting next month. Alongside the ongoing Phase II lupus study, we are working closely with Lilly on designing a Phase II study in atopic dermatitis patients. Lilly will sponsor and execute that study. It will be a relatively large placebo-controlled trial, and we expect the design to be finished around the end of the year, with the study starting in the first half of 2023. Lilly is also planning a further Phase II study in an autoimmune indication that has not yet been announced, which we hope to reveal in the first half of 2023. As you can see, we have important data readouts over the next 12 months, and we look forward to continuing our collaboration with Lilly. With that, I'll turn the call over to JZ to talk about NKTR-255 and our preclinical programs. JZ?

Jonathan Zalevsky

executive
#4

Thanks, Brian. I'll start things off right now by providing the latest on our NKTR-255 program. NKTR-255, one of our therapeutic candidates, is a compound that activates the entire IL-15 pathway, delivering functional stimulation along with homeostatic regulation of IL-15 responses from immune cells — specifically natural killer cells, CD8 T cells, and immune memory subsets. As a complete agonist of that pathway, NKTR-255 is able to pair with a range of mechanisms, from targeted agents all the way to cell therapies such as CAR-Ts, and even immunological checkpoints, with the goal of potentially boosting how well those agents work. Through our initial dose escalation efforts involving NKTR-255, we've noticed a steady rise in natural killer cells and CD8 T cells spanning several tumor types, such as multiple myeloma, non-Hodgkin's lymphoma, colorectal cancer, and head and neck cancer. Increases in NK cells have reached as much as ninefold, and because our pharmacokinetic profile is extremely predictable, we can administer NKTR-255 on a 3- or 4-week schedule. What's more, we're seeing gains in NK and CD8 T cells even among the hardest-to-treat patients, such as multiple myeloma patients whose bone marrow is compromised, while finding no rise in T regulatory cells within peripheral blood — yet another highly significant quality of NKTR-255. Back in April, we revealed that our updated development strategy for NKTR-255 centers on the critical areas where an IL-15 candidate can stand out and play to its strengths. On top of that, our strategy involves tapping external collaborations with partners to produce proof-of-concept data. Our collaborators are carrying out the initial development focus, pairing NKTR-255 with an anti-PD-L1 agent; during the quarter just passed, Merck KGaA launched the JAVELIN Bladder Medley Study. This randomized, open-label Phase II trial will evaluate avelumab combinations alongside 3 antitumor agents — NKTR-255, Trodelvy, and one of Merck's own anti-TIGIT therapeutic candidates — as maintenance treatment for bladder cancer patients whose disease hadn't progressed after a platinum regimen. As Howard mentioned before, avelumab is running at roughly a $500 million annualized revenue run rate in that setting. We believe NKTR-255 holds substantial promise there. Within the JAVELIN study, the NKTR-255 arm is set to be measured against avelumab monotherapy. Recruitment targets 252 patients in total: 72 patients in each combination arm, NKTR-255 included, plus 36 patients in the avelumab bladder therapy arm. Progression-free survival serves as the JAVELIN study's primary end point, and it ought to give us unambiguous comparative proof-of-concept data from these patients. In the registrational JAVELIN Bladder 100 trial, which involved the same patient population, the PFS reported for avelumab plus best supportive care came in at 3.7 months. Depending on how strong the data from this Phase II study turns out to be, the trial also offers NKTR-255 a potential route toward a future registrational trial in this setting. We anticipate the initial possible results from the Phase II trial toward the end of 2024. What makes us so enthusiastic about this trial is that, in contrast to every other PD-1 checkpoint inhibitor, avelumab is an IgG1 monoclonal antibody aimed at PD-L1. Being an IgG1, it possesses an Fc region that binds combined HER receptors on immune effector cells, functioning as a bridge that triggers ADCC-mediated tumor cell killing. Every other antibody targeting PD-1 and PD-L1 cannot induce antibody-dependent cellular cytotoxicity, since they carry a mutated Fc region or fall within the IgG4 subclass. Our scientific hypothesis holds that NKTR-255 will work synergistically alongside avelumab, producing cytotoxic CD8 effector memory cells and also generating NK cells that amplify avelumab's distinctive ADCC effect. Through this dual mechanism of action, which boosts the immune response and initiates ADCC, our distinctive combination can engage both innate and adaptive immunity. Our second trial of NKTR-255 paired with an anti-PD-L1 agent is a single-site collaboration study taking place at MD Anderson Cancer Center, in Dr. Steven Lin's clinic. That trial intends to enroll 30 patients and pairs NKTR-255 with durvalumab, also called IMFINZI, in its approved indication for Stage II to Stage III non-small cell lung cancer after chemoradiation. This matters because we understand that a large share of these patients develop lymphopenia after chemoradiation, and that condition is linked to worse progression-free survival. By adding an IL-15 stimulatory mechanism, we think we can potentially counteract this effect. The trial will evaluate the doublet's activity, and we anticipate initial data in early 2024. The next area we are focusing our development efforts on is advancing NKTR-255 as a potentiator of cell therapy across the wide and evolving cell therapy field. Since their first approvals back in 2017, use of chimeric antigen receptor T cells, or CD19 CAR-T therapy, has expanded substantially within the B-cell lymphoma treatment landscape. Even though these therapies deliver considerable treatment benefit for DLBCL patients who fail first- or second-line treatment, clinical responses to CAR-T often relapse over time in many patients. Consequently, there is a significant unmet need both to extend the duration of response and to push toward a greater frequency of complete responses. Preclinical data produced with the Fred Hutchinson Cancer Center has shown the promise of pairing NKTR-255 with CD19 targeted CAR T-cell therapies. At ASH 2019, adding NKTR-255 to a CD19 targeted CAR T-cell regimen in preclinical models of B-cell lymphoma was demonstrated to boost survival of CAR-T cells and diminish tumor growth relative to either treatment by itself. And at EHA 2019, researchers demonstrated that in vivo treatment using NKTR-255 and CAR-T cells led to rejection of a tumor reach out. So, taking into account what we found in those analyses, plus the information Howard mentioned earlier and the data we shared at ASH last year from relapsed patients — that data demonstrated a rise in baseline CAR-T cell levels following NKTR-255 — we're putting a lot of emphasis on getting a Nektar-sponsored trial started that pairs NKTR-255 with approved CAR-T therapy. What we're aiming for with this trial is to produce comparative results looking at NKTR-255 plus CAR-T against a placebo plus CAR-T in this particular setting, and the effort we're doing here might open the door to possible registrational trials down the road. From the time we made our announcement back in April, we've convened an advisory clinical board meeting so we could talk about the function of NKTR-255 or CAR-T therapy and also go over how the trial should be designed. We came away from that gathering with a great deal of excitement from the investigators, and we remain on schedule to finalize the trial design and get the trial going before the end of the first quarter of 2023. Given that timeline, we anticipate having initial data available in the third quarter of 2024. We've already got 2 trials in progress with partners outside our company to assess NKTR-255 when used together with CAR-T therapy. Dr. Crystal Mackall, the founding Director of the Stanford Center for Cancer Cell Therapy, is the sponsor of that first trial. At Stanford, they're pairing their proprietary CD19/CD22 bispecific CAR T-cell therapy with NKTR-255 in patients who have relapsed or refractory acute lymphoblastic leukemia. Even though the CR rate is hopped with this therapy, there's a substantial rate of relapse and a brief duration of response, along with a short median PFS.

Jonathan Zalevsky

executive
#5

We aim to assess if NKTR-255 is able to prolong the length of time patients experience CRs under this treatment plan. A total of 24 patients are slated for enrollment in the trial. Enrollment for this IST is progressing nicely, and we anticipate reporting findings from the initial handful of participants around late this year or in the early months of next year. Dr. Cameron Turtle's lab at the Fred Hutchinson Cancer Center is running the second trial. At The Hutch, they are pairing NKTR-255 with BREYANZI, also known as liso-cel, which is an approved CD19 CAR T-cell therapy, in 24 individuals with relapsed or refractory large B-cell lymphoma. We anticipate obtaining data from the initial few subjects in that trial during the first portion of 2023. The third and last priority area for NKTR-255 involves our ADCC combination trials that Nektar is sponsoring and that are currently in progress with NKTR-255. We have 2 active trials, in liquid and solid tumors, testing combinations with ADCC antibodies. We intend to share findings from the dose escalation segment of the liquid tumor trial later in 2023 at ASH; shifting now to our preclinical research efforts. We are building up our research pipeline, with a near-term emphasis on biologic initiatives that could be used in oncology and autoimmune disease. The initial effort we are advancing, NKTR-288, is a PEG conjugate of the protein interferon gamma. This molecule is engineered as a site-specific PEG attached to protein, aiming to alter how interferon gamma binds with one of its substrates and, more broadly, to substantially enhance the pharmacodynamic persistence of interferon gamma signaling. This initiative could apply to numerous possible indications, such as oncology, infectious diseases, and others. We are moving this effort forward and, beyond our own internal development, will seek out partnering possibilities to advance this program into clinical testing. Our next preclinical effort is aimed at tumor necrosis factor receptor 2, or TNFR2, and is progressing through a partnership with Biolojic design. Biolojic's antibody engineering strengths are particularly valuable for creating pepito-specific antibody-based agonists. Thus, we are collaborating with them on an innovative and distinctive bivalent agonistic antibody that targets TNFR2. TNFR2 is abundantly present on T regulatory cells, neuronal cells and endothelial cells, and TNFR2 agonism has been demonstrated to boost the suppressive impact and general functional characteristics of Tregs, and when it is missing, it is linked to CNS autoimmunity, while its existence has been tied to protective outcomes for neuronal cells and other cell populations and tissues within the body. We aim to select a candidate for IND-enabling studies by the close of the year. Our third initiative, which originated in our Nektar research labs, is likewise a novel biologic candidate centered on immune cell populations involved in tissue repair and tissue protection. This effort employs polymer engineering to alter a non-lymphocyte targeting cytokine. Additionally, this candidate's applications are something we feel great about, and we can't wait to share news on how things are going as these programs develop. Having said that, I'll now hand things over to Jill, who will walk us through our financial guidance.

Jillian Thomsen

executive
#6

Thanks, JZ, and good afternoon to all of you. Like Howard mentioned before, we've achieved meaningful strides when it comes to carrying out our restructuring plan and putting our revised strategic plan into effect. The financial guidance for 2022 that we shared on our April call has not changed. Our strategic plan is built to help move forward NKTR-358, NKTR-255, and several innovative preclinical programs. We finished the quarter in a solid financial spot, with roughly $625 million in cash and investments and no debt. The swift steps we took to resize our programs and workforce so they match our new strategic objectives create a cash runway reaching through the first half of 2025, which carries us past multiple key value-generating milestones for our pipeline. Let me recap the main actions taken in the second quarter to lower our continuing operating expenses; we cut our head count by about 70%, going from roughly 735 down to 225 employees. Measured on an annual run rate basis, that reduction equals about $120 million in yearly operating expense savings. We've worked to carry out the most efficient operational wind down of the BEMPEG program, in line with our commitment to patients and their physicians. The studies are being stopped and patients are moving over to standard of care options. We shut our R&D facility located in Hyderabad, India and have gotten strong interest from several parties wanting to buy the site. We're also seeking subleases for a substantial portion of our facilities in the San Francisco Bay Area, while still keeping enough office and laboratory space so our team can push our proprietary program ahead. Now let me shift to our second quarter results and remind everyone about our financial guidance. As I said before, we closed the second quarter with about $625 million in cash and investments, and we continue to plan on finishing the year with $440 million to $450 million. Our full year GAAP revenue guidance is unchanged and anticipated to land between $85 million and $95 million, which includes $15 million to $20 million of product sales along with $70 million to $75 million of noncash royalties. We anticipate recognizing the remaining revenue on a fairly ratable basis during the second half of the year; tied to our business restructuring and reduction in head count, we still anticipate recognizing impairment charges totaling $150 million to $160 million; during the second quarter, we recognized $106 million of this restructuring charge, including $57 million of noncash impairment charges tied to the write-off of facilities, IT systems and laboratory equipment, plus approximately $28 million of severance. The impairment charge in Q2 also includes $21 million in BEMPEG program wind-down costs, with the most significant portion tied to ongoing clinical study costs during the wind-down. The wind-down process will keep going in Q3 and Q4. And under GAAP, we will record the remaining costs as incurred within the impairment line item of our income statement. For research and development spending, our forecast remains in the range of $240 million to $250 million, and that figure includes $40 million to $45 million of noncash depreciation along with stock compensation expense. On general and administrative costs, we continue to anticipate a range of $90 million to $95 million, which includes $25 million to $30 million of noncash depreciation and stock compensation expense. Then, for noncash interest expense, we expect a figure somewhere between $25 million and $30 million, tied to how we previously monetized our royalty stream. Turning now to the period after 2022, the updated strategic plan we've put together targets average annual net cash used in operations somewhere between $150 million and $175 million. That amounts to a $225 million to $225 million decrease relative to the spending level we had before the restructuring that was announced in April. Let me remind everyone that our intention is to cover in full Nektar's 25% portion of Phase III development for the NKTR-358 program, which falls under our collaboration agreement with Eli Lilly; beyond that, a set of potential milestones can be earned by us as this program advances through late-stage development, and those are worth a total of $250 million. The milestones break down as follows: $50 million when the first patient is enrolled in a Phase III clinical study; $75 million at the point the Phase III — when the first Phase III study hits its primary endpoints, $75 million for the first BLA approval in the U.S.; and $50 million upon the first European approval. As we've told you before, these milestones play an essential role in our collaboration with Lilly, since they effectively assist us in covering an additional 25% of the Phase III study cost. We appreciate your participation on today's call. At this point we'd like to take your questions. Chad?

Chris Shibutani

analyst
#7

The advances being achieved throughout these programs are encouraging to see. Let me direct my question toward 358 and the extra data set to be revealed in September. To clarify, has any information come our way regarding the psoriasis program? My understanding is that Lilly has not yet toplined that one. Should we anticipate that September will bring that as well, alongside the AD data? Also, when it comes to 358, and as we think through the various immune mediated disease indications, could you help us grasp whether you believe that specific compound, this approach, 358 could hold an advantage for particular indication types? Some early signs looked promising in lupus. In UC, I believe there was a bit of disappointment. If you could simply help us understand how to approach that along with the September readout.

Vivian Wu

executive
#8

Thanks, Chris. Brian is going to take that question.

Brian Kotzin

executive
#9

All right, thanks for those. I believe I can handle them one at a time, though I might need you to jog my memory on the third. The initial one concerned whether we'd be sharing data from the psoriasis trial; and indeed, the response is affirmative. At EADV in September, there will be 2 presentations. The first of those will focus on the psoriasis study — the Phase Ib trial in psoriasis. The other is going to be a Phase Ib summary of the Phase Ib conducted in atopic dermatitis. I'd like to stress that regarding the atopic dermatitis presentation, while some interim data has already been shown, what we'll be presenting — Lilly will be presenting — is the complete efficacy and safety data set. Up to now, only interim data has been presented. Furthermore, it's worth pointing out that we will also be sharing additional endpoints that are likewise utilized in atopic dermatitis studies. What has us so enthusiastic about these presentations is that you'll get to observe the degree of improvement and, as we've stressed, the durability observed following the drug treatment, once treatment was discontinued. Now, I realize you posed a second question, but I'll need a reminder on what it was.

Chris Shibutani

analyst
#10

To start with, regarding 358, there are some difficulties to address. What is it about this that suggests it will probably succeed? Or what insights have you gained thus far — maybe mechanistically distinctive ones — from the various conditions where we're conducting early-stage clinical trials?

Brian Kotzin

executive
#11

Yeah. That's an excellent question. My view is that what we're revealing here is novel biology. Because of that, we're essentially at the forefront when we move into these conditions, and the way this works — triggering regulatory T cells to suppress the immune reactions fueling these illnesses — represents new biology. And as you pointed out, we've observed some remarkably encouraging results in lupus as well as in specific dermatologic skin conditions, namely atopic dermatitis. You brought up too that we had a — we halted the trial in ulcerative colitis. What deserves emphasis is that the T cells propelling disease across these separate conditions differ greatly. Consequently, the T cell driving factor in ulcerative colitis follows a pathogenic route quite unlike what we've witnessed in lupus or what we understand to be present in lupus, and likewise in atopic dermatitis and psoriasis. So once more, I believe we're seeing — novel biology is coming to light. I'd add that the reality we observed diminished efficacy in the UC trial, that we failed to see the efficacy witnessed in the other conditions, aligns with what others have described — and that applies both to this mechanism and to alternative mechanisms; achieving an effect in ulcerative colitis simply demands either larger doses or different categories of treatments, which does not hold true for these other conditions. So thank you once more for raising that.

Cheng Li

analyst
#12

Cheng here, calling in for Jay. So, regarding 358 first — I believe you'd said before that a Phase II trial in atopic dermatitis would kick off during the third quarter. But now it looks as though that study will likely get going in '23. So I'm curious: what led to the hold-up, and which factors are gating it? Then, on a separate note for 255, it appears you're quite enthusiastic about the chance to pair 255 with CAR-T. So what would prompt a study sponsored by Nektar in that setting, and that's it from me.

Vivian Wu

executive
#13

Thanks, Cheng. Brian is going to take the first portion of your question, and after that JZ will handle the second.

Brian Kotzin

executive
#14

The rationale behind our ongoing work on the design — the design of the Phase II dose-ranging study in atopic dermatitis is complex, all right? And that's essentially the source of the delay. It's simply requiring more time from us to determine what the ideal — the ideal, the most optimal kind of design would be for the questions at hand. I'd say the landscape in atopic dermatitis is shifting. And this has likewise led us to devote additional time to the study design. And that is the reason the study is — initiation is scheduled for 2023 instead of the end of this year.

Jonathan Zalevsky

executive
#15

This is JZ. Regarding what you asked second, absolutely, we're quite enthusiastic about what NKTR-255 might do alongside CAR-T treatments. I actually walked through a great deal of the information we've shared across roughly the past 3 years, during which we've examined this pairing in increasingly sophisticated test systems — beginning with straightforward in vitro work. Take the CAR-T cells: they carry IL-15 receptors, correct? Signaling through those receptors is possible, proliferation of the cells can be triggered, and anti-apoptotic markers can be induced — really basic in vitro experiments — then progressing to progressively more elaborate in vivo research and cell models, and finally advancing into various patient contexts. To be clear, you raised the matter of what would prompt us to launch a sponsored study. Well, as a matter of fact, we genuinely are conducting a sponsored study — this being the one I referenced previously during this call, in which we will assess placebo alongside standard of care CAR-T therapies compared with 255 administered 2 to 3 weeks following CAR-T therapy transplant in patients. So that study is truly going to happen. Nektar is set to serve as the sponsor. We're eager to get that study underway. Our expectation is to launch it near the close of this year. And, as I noted before, we anticipate having results from it during 2024.

Jialiang Liang

analyst
#16

This is JL filling in for Jess. Our first question concerns the interim analysis of 358 in the Phase II lupus study. From the press release, it appears that in addition to safety, efficacy is also included in that interim analysis. So we're curious: does that suggest a futility analysis has been conducted using both efficacy and safety? And if safety is included in the interim analysis, what kind of safety — sorry, what kind of efficacy data has the committee reviewed? Have they examined the primary end point or any of the secondary efficacy endpoints? Our second question relates to the cash runway. We understand you've guided that your cash runway could extend into the first half of 2025. But is that based only on 255 and 358, or does it also account for the possibility that you might announce new clinical assets between now and the first half of 2025?

Vivian Wu

executive
#17

Brian will address the 358 question, and then Jill will take the financial one.

Brian Kotzin

executive
#18

To protect the study’s integrity and keep both patients and investigators blinded, we’re not able to disclose the data that the interim assessment committee reviewed for the interim analysis. As you’re aware, and as we’ve stated, this trial remains ongoing, and preserving its integrity is truly essential. The interim analysis looked at both efficacy and safety among roughly 60% of patients who had finished the 24-week treatment period. And once more, based on the prespecified criteria, the study continues as planned. Neither Lilly nor we reveal the prespecified criteria applied in the interim analysis. What we can say is that no futility analysis was included in this study; even so, the interim assessment committee was permitted to halt the study if efficacy was inadequate relative to placebo. So — and naturally, they also had the chance to stop it over any significant safety issue. I’d also like to remind you that this is a placebo-controlled trial, and it compares 3 separate doses of RESPEG against placebo. So yes, thanks again for asking.

Jillian Thomsen

executive
#19

Jill here. Regarding your second question, naturally, assuming the preclinical programs keep generating favorable results, what we intend to do is keep advancing those programs that JZ walked you through. Beyond that, as JZ noted, we're going to look into a partnership for NKTR-288, along with other possibilities as they come up.

Mary Kate Davis

analyst
#20

This is Mary Kate filling in for Greg. How do you plan to position NKTR-358 in atopic dermatitis, and what might stand out regarding the mechanism of action or the responses you've observed that could set it apart?

Vivian Wu

executive
#21

Thanks, Mary Kate. Brian is going to take that question.

Brian Kotzin

executive
#22

So I suppose that ties into what we're currently debating — specifically, how 358 should be positioned, particularly given the shifting environment I brought up earlier. Let me stress right off the bat that 358 works through an entirely distinct mechanism of action versus the other medications sitting in the atopic dermatitis arena, all right? Take the standard of care, DUPIXENT — it blocks the IL-4, IL-13 pathway. Several other drugs that have now entered the market essentially target that same pathway, the IL-13 pathway, meaning they're quite closely related. Meanwhile, the other big players either approved or being studied for atopic dermatitis are the JAK inhibitors, and there's an entire backstory with those JAK inhibitors. What matters most to stress at this point, though, is that NKTR-358 operates through a totally different mechanism. Basically, we're examining endpoints that look quite similar across these trials. And we recognize there will be subsets of patients who respond to our mechanism yet not to the others, and the reverse will also hold true. That's the way we intend to set this drug apart.

Jerry Gong

analyst
#23

Jerry Gong here, filling in for Mara Goldstein. First up, regarding possible chances for business development — I realize you've already discussed this topic previously. Have you pinpointed possibilities involving additional candidates, for instance a 255 or other candidates at earlier stages too? Also, would there be a particular kind of deal you'd be keenest on, like one that's front loaded or tied to a milestone?

Vivian Wu

executive
#24

Thanks, Jerry; Howard is going to take that one.

Howard Robin

executive
#25

Yes, that's a great question. So, we've got substantial business development work going on around NKTR-255, though at this point I don't believe we're considering out-licensing it at all. There are definitely a lot of collaborations. We've already been partnering with several companies that have been putting NKTR-255 into their programs. And we're observing some very compelling results, and they're observing very compelling results too. So I really do think you'll see collaborations form around NKTR-255. But I believe they'll be fairly diverse, and that's because in cell therapy there are many different opportunities; the space is actually getting quite broad. And as I mentioned earlier, I'd like NKTR-255 to become the go-to potentiator across a number of different cell therapies, not only one; so given that, I see plenty of room for collaboration. I do believe Nektar will hold onto NKTR-255 as a wholly-owned asset for now.

Tsan-Yu Hsieh

analyst
#26

So when it comes to the CAR-T combo, JZ, clearly there are plenty of logistical matters happening behind the scenes that you also need to work through — what the therapy costs, what hospitals charge. I'm just wondering: from a cost standpoint, do you need a partner to buy in before you can move forward and run this trial?

Vivian Wu

executive
#27

Thanks, Andy; JZ is going to take that question.

Jonathan Zalevsky

executive
#28

Andy, I appreciate you raising that. You're definitely right—these treatments come with a high price tag. And on top of that, as you're aware, when a patient receives CAR T, they need to stay in very close geographic proximity to the hospital, since these patients require such intensive monitoring. That means they're either admitted to the hospital or staying practically right across the street, if you follow my meaning. So every one of those factors was something we factored in and considered as we thought through how to operationalize and carry out this study. And essentially, we're capable of running this study independently. There's no need for us to bring in another company to get the study done. That also encompasses the reality that access to the cell therapy itself—keep in mind, in numerous instances, it's actually reimbursed by insurance since it's being used in the on-label setting. Regardless, our goal is to make this study as accessible as possible for investigators and for patients too. So we factored in logistical aspects, timing aspects. As you're aware, Andy, the supply chain for certain autologous products has even proven difficult. In certain instances, we've factored those considerations in as well. We have strong confidence in our ability to carry out the study. We're collaborating with some of the top centers across the United States—specifically, facilities with substantial bed capacity that handle a great many CAR-T patients using these approved on-label products. So we're fairly confident about getting the study done. And as I stated earlier, we anticipate launching it near the end of the year. Thank you for your question, Andy.

Jiale Song

analyst
#29

Thanks. Perhaps just one more on this — regarding the 2C design in the Phase II trial for atopic dermatitis, with the Phase Ib full data coming in September, would you take the Phase Ib results into account when designing that study, or will there still be some go-or-no-go calls to be made about whether to proceed with the Phase II?

Ben Burnett

analyst
#30

Thank you, Roger. Brian is going to handle that one.

Brian Kotzin

executive
#31

No — the results from the Phase Ib study are known to us, and we're proceeding with the dose-ranging Phase IIb design. In this disease indication, we've shown proof-of-concept, and we are moving ahead.

Analyst

analyst
#32

Kelly Brees here, filling in for Ben Burnett. We've got just a single question about NKTR-255. We were wondering whether combining NKTR-255 with CAR-T opens up any possibility to reduce lymphodepletion, or even skip it altogether?

Vivian Wu

executive
#33

Vivian Wu will take that question.

Jonathan Zalevsky

executive
#34

Absolutely, Vivian, and Kelly, I appreciate that question. That's a really thought-provoking one. Of course, as you're aware, at this point in time, the approach that's used most commonly involves Cy/Flu, correct? And there are numerous problems associated with that, from the perspective of the patient and also regarding whether some of those components can even be obtained, as you know if you keep a close eye on this area. Now here's the thing: we've long held this hunch that with 255, there could be a chance to genuinely take a totally different tack when it comes to designing a conditioning regimen. Perhaps it need not be so much of what you might call, for want of a better phrase, a sledgehammer hitting the patient's immune system. Other regimens might be usable, and it's even possible you could leave it out entirely; that would definitely belong to the far more exploratory category of effort. Without a doubt, the investigators we collaborate with have a tremendous amount of interest in this matter. And a number of them have put forward and exchanged some of their scientific ideas regarding it. One point that sits at the heart of everything here is that we are aware that a key function of lymphodepletion is in fact to establish a cytokine environment within the patient that is strongly linked to a successful lymphocyte transplant; essentially, it's a highly supportive setting for lymphocytes. This comes about essentially by depleting lymphocytes and prompting the body toward adaptively repopulating the immune system. So that's the way you'd want to transplant into that sort of systemic milieu; and clearly, with a mechanism such as 255 and agonism of the IL-15 pathway, given that this cytokine is so crucial, perhaps that alters things, and our investigators have interest in it. Having said all that, this would fall more within exploratory efforts. In my view, it's an opportunity for the future. We'll begin by employing the sort of on-label method for the CAR-T products in our clinical study. So that's going to be applied in the usual fashion, yet one of the longer-term possible opportunities for 255 is in fact to potentially alter the conditioning regimen. Excellent question.

Daina Graybosch

analyst
#35

Quite a few strong questions have come in already, so I'll move on to 2 regarding NKTR-255, both tied to certain solid tumor combinations you're working on. Starting with the avelumab maintenance setting in bladder cancer. To me, that's a genuinely compelling trial. The biomarkers you mentioned are intriguing as well — it appears patients whose NK cells have higher affinity respond more favorably. My specific wonder is this: for NKTR-255, have you generated data demonstrating that patients whose CD16 NT cells are lower affinity can be potentiated by NKTR-255? Are those patients going to benefit? Or is your expectation that the higher affinity NT cell patients are the ones you'll help do better? Then for my second question, about the MD Anderson trial of post-CRT in combination with durvalumab: can you verify whether that is a single-arm study? That indication, I'm aware, is one where results fluctuate considerably across sites, so how do you believe a single-arm design lets you gain a solid read on how outcomes stack up against historical data absent a randomized arm?

Vivian Wu

executive
#36

Thanks, Daina; JZ is going to take that one.

Jonathan Zalevsky

executive
#37

Absolutely, and thanks for that, Daina. Your initial point concerned avelumab maintenance along with the NK compartment, so Merck put out a truly fascinating paper from JAVELIN 100, which was the registrational trial. What they demonstrated across the 4 slots, plus certain further analyses, is that those patients whose NK cell baseline levels were highest at the moment of randomization into maintenance ended up faring best of all. When you broke down the results, those patients truly fell into what you could call the high-efficacy quartile among the outcomes they saw. That really made it clear that an environment rich in NK cells was highly advantageous; now, regarding how thorough the phenotyping was, I'm not aware they necessarily carried out extensive work of that kind in that particular study. But addressing your precise point, mechanistically speaking, in this instance the CD16-positive NK cell would be the single most essential, since we understand there's 56bright, 16dim, 56dim, 16bright, correct? And it's the 16bright subset that takes part in the ADCC reaction. They express FCGammaR3A at elevated levels. What we have observed across our numerous first-in-human trials, in solid tumors and in liquid tumors alike, is that we raise CD16-positive NK cells; demonstrating that mattered greatly to us as a very early biomarker of NKTR-255 biology, because as we move forward into ADCC combinations, even within the heme setting such as in our daratumumab and rituximab studies, we need certainty that we are increasing CD16-positive NK cells. So everything there appears highly, highly encouraging. Merck likewise regarded all of it as highly, highly encouraging; that's the reason the two of us are so very, very thrilled to have 255 as an arm within JAVELIN Bladder Medley. It genuinely examines a composite mechanism added onto BAVENCIO; and as I said, BAVENCIO is genuinely one of a kind, since it truly is the sole PD-L1 IPG 1 Fc, and it genuinely provides us the chance to potentially have 2 mechanisms simultaneously by adding 255. Regarding your following question about the investigator-sponsored study, that is in fact a single-arm trial, and it's a single-site trial at MD Anderson. Something significant here is that Dr. Steven Lin is a highly seasoned thoracic oncologist, and he possesses considerable experience using durva in this context; now, another thing this trial is measuring is — your observation about regional effect differences is quite important. This trial is specifically examining the lymphodepleted patient population that experiences lymphodepletion after chemoradiation, correct? So it's genuinely focused on the most severe subset of patients; and Dr. In his lab, Lin demonstrated that when IL-15 is added in that context using his preclinical models, it genuinely rescues lymphodepletion and, in fact, brings back sensitivity to PD-L1 blockade. Therefore, the scientific hypothesis being tested here is that there's a chance to overcome and fix a lymphodepleted effect observed among this subset of patients, and after that we ought to be able to boost efficacy through combining 255 with durva in these lymphodepleted patients. Another positive aspect is that MD Anderson truly does treat a large number of patients, correct? Consequently, they likewise possess considerable historical experience that they can draw upon and contribute toward interpreting the study, even just inside their own institution. Thus, we're genuinely eager about that study. In my view, it's genuinely well designed as a signal-seeking study. And should the data from it appear promising, we would then advance into proper, far, far bigger studies that are randomized with suitable comparators. Thank you for your questions.

Howard Robin

executive
#38

Alright, thanks everybody for being with us today. There were a lot of genuinely good questions. Today, I believe we've laid out the steady advancement we're making throughout our pipeline and partnered programs as part of our strategic reorganization, and we think these programs could potentially meet the needs of substantial patient populations and offer the chance to generate considerable value for our shareholders. We're eager to keep executing on these key programs and to build on our core research capabilities and distinctive competencies. I want to express my appreciation to all of our employees for what they do and for their hard work, and I also want to thank our shareholders for sticking with us, and we're looking forward to giving you updates as we make progress. So keep watching. Thanks for being here.

Operator

operator
#39

Thanks a lot, sir. That brings the conference to a close. We appreciate your joining us for today's presentation. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.